产品
编 号：F755331
分子式：C23H19ClN2O
分子量：374.86
分子式：C23H19ClN2O
分子量：374.86
产品类型
规格
价格
是否有货
结构图
CAS No: 2750233-50-0
产品详情
生物活性：
Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer.
体内研究：
Antitumor agent-79 (40 mg/kg; p.o. twice a week for 4 weeks) shows antitumor effects in mice xenograft models.Animal Model:6?8 weeks old male athymic nude mice with hepatocellular carcinoma (Mahlavu cells) and breast (MDA MB-231 cells) xenografts
Dosage:40 mg/kg
Administration:Oral gavage; 40 mg/kg; twice a week for 4 weeks
Result:Significantly reduced the tumor volume following 4 weeks treatment with 40% reductions of tumor volumes in the Mahlavu xenografts. Resulted in about a 50% decreased in tumor volumes as compared to the control group in MDA-MB-231 xenografts. Showed well tolerated in vivo and neither significant bodyweight loss nor toxic effects or mortality were observed.
体外研究：
Antitumor agent-79 (0.15-40 μM; 72 h) shows in vitro growth inhibitory activitiesagainst hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM.Antitumor agent-79 (5 μM; 48 h) induces cell apoptosis by increasing the PARP cleavage.
Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer.
体内研究：
Antitumor agent-79 (40 mg/kg; p.o. twice a week for 4 weeks) shows antitumor effects in mice xenograft models.Animal Model:6?8 weeks old male athymic nude mice with hepatocellular carcinoma (Mahlavu cells) and breast (MDA MB-231 cells) xenografts
Dosage:40 mg/kg
Administration:Oral gavage; 40 mg/kg; twice a week for 4 weeks
Result:Significantly reduced the tumor volume following 4 weeks treatment with 40% reductions of tumor volumes in the Mahlavu xenografts. Resulted in about a 50% decreased in tumor volumes as compared to the control group in MDA-MB-231 xenografts. Showed well tolerated in vivo and neither significant bodyweight loss nor toxic effects or mortality were observed.
体外研究：
Antitumor agent-79 (0.15-40 μM; 72 h) shows in vitro growth inhibitory activitiesagainst hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM.Antitumor agent-79 (5 μM; 48 h) induces cell apoptosis by increasing the PARP cleavage.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备